Combinatorial therapy regimens combining CXCL10-targeted agents with ICIs, JAK/STAT inhibitors or PI3K/Akt pathway modulators should also be investigated in clinical trials, especially in resistant or immune-excluded tumor types. Here, AKT1 is linked to neoplasm.